Curis Inc
CRIS1.570USD
-0.060-3.68%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
16.43MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Curis Inc Unternehmen
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Unternehmensinformationen
BörsenkürzelCRIS
Name des UnternehmensCuris Inc
IPO-datumAug 01, 2000
CEOMr. James E. Dentzer
Anzahl der mitarbeiter33
WertpapierartOrdinary Share
GeschäftsjahresendeAug 01
Addresse128 Spring Street
StadtLEXINGTON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02421
Telefon16175036500
Websitehttps://www.curis.com/
BörsenkürzelCRIS
IPO-datumAug 01, 2000
CEOMr. James E. Dentzer
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+37.97%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+660.71%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+37.97%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+660.71%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bleichroeder LP
8.63%
Armistice Capital LLC
8.61%
Satterfield (Thomas A Jr)
7.39%
Maverick Capital, Ltd.
5.26%
M28 Capital Management LP
4.34%
Other
65.76%
Aktionäre
Aktionäre
Anteil
Bleichroeder LP
8.63%
Armistice Capital LLC
8.61%
Satterfield (Thomas A Jr)
7.39%
Maverick Capital, Ltd.
5.26%
M28 Capital Management LP
4.34%
Other
65.76%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
18.74%
Hedge Fund
16.28%
Individual Investor
7.53%
Venture Capital
1.66%
Investment Advisor/Hedge Fund
1.46%
Research Firm
0.78%
Other
53.54%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
101
5.57M
46.46%
+1.30M
2025Q1
112
5.58M
53.29%
+1.28M
2024Q4
119
3.88M
45.77%
+849.35K
2024Q3
129
2.03M
33.69%
-831.36K
2024Q2
151
2.33M
39.45%
-531.00K
2024Q1
226
2.12M
35.82%
-1.17M
2023Q4
249
2.07M
35.17%
-1.64M
2023Q3
265
2.42M
42.19%
-1.36M
2023Q2
279
1.78M
36.08%
-2.05M
2023Q1
312
1.73M
35.82%
-2.73M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bleichroeder LP
1.04M
8.63%
+515.12K
+98.96%
Mar 31, 2025
Armistice Capital LLC
1.03M
8.61%
+957.37K
+1259.69%
Mar 31, 2025
Satterfield (Thomas A Jr)
886.71K
7.39%
+274.49K
+44.84%
Mar 31, 2025
Maverick Capital, Ltd.
631.83K
5.26%
--
--
Mar 31, 2025
M28 Capital Management LP
521.06K
4.34%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
303.19K
2.53%
+32.94K
+12.19%
Mar 31, 2025
CM Management, LLC
240.00K
2%
+20.00K
+9.09%
Mar 31, 2025
Alyeska Investment Group, L.P.
189.38K
1.58%
-8.84K
-4.46%
Mar 31, 2025
Samsara BioCapital, LLC
185.94K
1.55%
-12.27K
-6.19%
Mar 31, 2025
Renaissance Technologies LLC
96.87K
0.81%
+2.80K
+2.98%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Datum
Art
Verhältnis
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
